Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.76 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.76 |
| ▸ | MAPT | P10636 | 3/20 | 0.64 |
| ▸ | GAA | P10253 | 2/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.60 |
| ▸ | THRB | P10828 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL404263 | 1.00 | ALDH1A1 (0.76) | ALDH1A1SMN1; SMN2MAPTGAAHTT | |
| SCHEMBL17249588 | 1.00 | ALDH1A1 (0.76) | ALDH1A1SMN1; SMN2MAPTGAAHTT | |
| SCHEMBL10029261 | 1.00 | ALDH1A1 (0.76) | ALDH1A1SMN1; SMN2MAPTGAAHTT | |
| SCHEMBL20006251 | 0.88 | ALDH1A1 (0.60) | ALDH1A1SMN1; SMN2MAPTGAAHTT | |
| SCHEMBL404562 | 0.88 | ALDH1A1 (0.78) | ALDH1A1SMN1; SMN2MAPTGAAHTT | |
| SCHEMBL10029228 | 0.88 | ALDH1A1 (0.78) | ALDH1A1SMN1; SMN2MAPTGAAHTT | |
| SCHEMBL17249585 | 0.86 | ALDH1A1 (0.76) | ALDH1A1SMN1; SMN2MAPTGAAHTT | |
| SCHEMBL404251 | 0.86 | ALDH1A1 (1.00) | ALDH1A1SMN1; SMN2MAPTGAAHTT | |
| SCHEMBL10029232 | 0.86 | ALDH1A1 (0.76) | ALDH1A1SMN1; SMN2MAPTGAAHTT | |
| SCHEMBL405810 | 0.86 | ALDH1A1 (0.76) | ALDH1A1SMN1; SMN2MAPTGAAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9862683-B2 | Methods of preparing Tecovirimat | SIGA TECHNOLOGIES, INC. (US) | 2018-01-09 | — | — | US | disclosed |
| US-20170088517-A1 | METHODS OF PREPARING TECOVIRIMAT | SIGA TECHNOLOGIES, INC. (US) | 2017-03-30 | — | — | US | disclosed |
| US-20150322010-A1 | METHODS OF PREPARING TECOVIRIMAT | SIGA TECHNOLOGIES INC. (US) | 2015-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150322010-A1 | METHODS OF PREPARING TECOVIRIMAT | TYMP, NUDT1, HPRT1 | ALDH1A1 2593/4885SMN1; SMN2 672/4885MAPT 834/4885 |
| US-20170088517-A1 | METHODS OF PREPARING TECOVIRIMAT | TYMP, NUDT1, HPRT1 | ALDH1A1 2593/4885SMN1; SMN2 672/4885MAPT 834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.